ALEC - Alector Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-8.679M

Cash

669.3M

Avg Qtr Burn

-50.99M

Short % of Float

10.07%

Insider Ownership

11.04%

Institutional Own.

81.57%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Latozinemab (AL001) (progranulin) Details Frontotemporal dementia with a granulin mutation, Dementia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AL002 (TREM 2) Details Alzheimer's disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Latozinemab (AL001) (progranulin) Details Frontotemporal dementia with C9orf72 mutation, Dementia, Chronic kidney disease, Kidney disease, Amyotrophic lateral sclerosis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AL101 (Progranulin) Details Alzheimer's disease, Parkinson's disease, Neurological disorder	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AL003 (SIGLEC 3) Details Alzheimer's disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.